Journal cover Journal topic
Journal of Bone and Joint Infection An open-access journal of the European Bone and Joint Infection Society and the MusculoSkeletal Infection Society
Journal topic
Volume 5, issue 1
J. Bone Joint Infect., 5, 16–24, 2020
https://doi.org/10.7150/jbji.40667
© Author(s) 2020. This work is distributed under
the Creative Commons Attribution 4.0 License.
J. Bone Joint Infect., 5, 16–24, 2020
https://doi.org/10.7150/jbji.40667
© Author(s) 2020. This work is distributed under
the Creative Commons Attribution 4.0 License.

Review 01 Jan 2020

Review | 01 Jan 2020

Oral Flucloxacillin for Treating Osteomyelitis: A Narrative Review of Clinical Practice

Helga Preiss1, Philipp Kriechling2, Giulia Montrasio1, Tanja Huber3, İmke Janssen4, Andreea Moldovan5, Benjamin A. Lipsky6, and İlker Uçkay7 Helga Preiss et al.
  • 1Internal Medicine, Baden Hospital, Baden, Switzerland
  • 2Orthopaedic Surgery, Balgrist University Hospital, Zurich, Switzerland
  • 3Hospital Pharmacy, Balgrist University Hospital, Zurich, Switzerland
  • 4Internal Medicine, Zollikerberg Hospital, Zollikon, Switzerland
  • 5Infectiology, St. Constantin Hospital, Braşov, Romania
  • 6Department of Medicine, University of Washington, Seattle, Washington, USA
  • 7Infectiology, Balgrist University Hospital, Zurich, Switzerland

Keywords: oral flucloxacillin, osteomyelitis, literature review, clinical treatment, clinical remission

Abstract. Flucloxacillin (FLU) administered by the oral route is widely used for treating various infections, but there are no published retrospective or prospective trials of its efficacy, or its advantages or disadvantages compared to parenteral treatment or other antibiotics for treating osteomyelitis. Based on published in vitro data and expert opinions, other non-β-lactam oral antibiotics that have better bone penetration are generally preferred over oral FLU. We reviewed the literature for studies of oral FLU as therapy of osteomyelitis (OM), stratified by acute versus chronic and pediatric versus adult cases. In striking contrast to the prevailing opinions and the few descriptive data available, we found that treatment of OM with oral FLU does not appear to be associated with more clinical failures compared to other oral antibiotic agents. Because of its narrow antibiotic spectrum, infrequent severe adverse effects, and low cost, oral FLU is widely used in clinical practice. We therefore call for investigators to conduct prospective trials investigating the effectiveness and potential advantages of oral FLU for treating OM.

Publications Copernicus
Download
Citation